Skip over navigation
Banner
Industry
Directory Facilities Technology Transfer Economic Develop. TX BioHistory (TM)
Career
Job Search Post a Job Submit Resume Destination TX
News/Events
Local TX News Submit News Release Calendar Submit Event CEO Reading
Patient
Clinical Trials Local Support National Resources
Education
K-12 Higher Ed BioEd Reading
About
Advertising Feedback Home
 
About
 Advertising
 Feedback
 Home
Quick Links
 Directory
 Job Search
 Facilities
 Calendar
 Advertising
Community Service Ad: CDC Get Vaccinated
Events
 
Facilities
 

NEW University of Washington Basic Bioscience Certificate starts Jan 2009

UW M.S. in Biomedical Regulatory Affairs with evening classes for working professionals


Medchem Source

Local News

Submit News Release


Search Articles: 

  • Johnson & Johnson extends tender offer for Mentor Corporation  Johnson & Johnson announced it has extended its previously announced cash tender offer, through its wholly owned subsidiary, Maple Merger Sub, for all outstanding shares of common stock of Mentor Corporation until 5:00 p.m. (Eastern time), on January 16, 2009, unless further extended.
    Johnson & Johnson January 06, 2009  
  • Monsanto announces yield gains with Deltapine Class Of 09  Monsanto Company announced its D&PL business will market five new varieties as the Deltapine Class of 09 for the coming production season. These varieties were introduced during the 2009 Beltwide Cotton Conferences that have brought the cotton industry together in San Antonio.
    Monsanto Company January 06, 2009  
  • Abbott completes acquisition of Ibis Biosciences, a subsidiary of Isis  Isis Pharmaceuticals and Abbott announced that Abbott has completed its purchase of Ibis Biosciences, an Isis subsidiary, for a closing purchase price of $175 million.
    Isis Pharmaceuticals, Inc. January 06, 2009  
  • MedImmune submits Marketing Authorisation Application in EU for intranasal flu vaccine  MedImmune, the global biologics unit of AstraZeneca, announced that it has submitted a Marketing Authorisation Application (MAA) for its nasal spray live attenuated influenza vaccine (LAIV), which is now being reviewed by the European Medicines Agency (EMEA).
    AstraZeneca January 06, 2009  
  • Dick Bond leaving Tyson Foods  Dick Bond, president and chief executive officer of Tyson Foods, announced he is leaving the company, effective immediately. Leland Tollett, former chairman and CEO of the company, has agreed to return to the company as President and CEO on an interim basis.
    Tyson Foods, Inc. January 05, 2009  
  • PPD enters into strategic collaboration with Merck  PPD announced it has entered into a strategic collaboration with Merck & Co. involving vaccine testing and assay development. Under the agreements, PPD purchased Merck's 130,000 square-foot vaccine testing laboratory and related equipment in Wayne, Penn.
    PPD, Inc. January 05, 2009  
  • Albemarle completes the sale of its Port de Bouc, France facility to ICIG  Albemarle and International Chemical Investors Group (ICIG) announced today that Albemarle Chemicals SAS, a wholly owned affiliate of Albemarle Corporation, has completed the sale of its facility in Port de Bouc, France to Azur Chimie SAS, a wholly owned affiliate of ICIG.
    Albemarle Corporation January 02, 2009  
  • FDA Cardio Renal Advisory Committee to review Daiichi Sankyo, Lilly drug prasugrel  Daiichi Sankyo Company and Eli Lilly and Company confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will review prasugrel during an advisory committee hearing on February 3, 2009.
    Eli Lilly and Company December 31, 2008  
  • Johnson & Johnson completes acquisition of Omrix Biopharmaceuticals  Johnson & Johnson announced the completion of its previously announced acquisition of Omrix Biopharmaceuticals, a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products.
    Johnson & Johnson December 30, 2008  
  • Celera and Abbott revise strategic alliance  Celera and Abbott announced a revision of the strategic alliance agreement between the two companies. Under a new distribution agreement, Abbott will exclusively distribute certain molecular diagnostic products manufactured by Celera.
    Celera Corporation December 29, 2008  

   (next 10 articles)

Search Articles: 


Submit News Release

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page

© 2009 Info.Resource, Inc. All rights reserved.
Privacy Policy . Terms of Use . Advisory Board . Advertising

TexasLifeScience.com is owned and published by Info.Resource, Inc..